Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-4919
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells ; day:27 ; month:10 ; year:2022 ; pages:1-17
Molecular and cellular biochemistry ; (27.10.2022), 1-17
- Urheber
-
Jones, Dylan
Whitehead, Clarissa A.
Dinevska, Marija
Widodo, Samuel S.
Furst, Liam M.
Morokoff, Andrew P.
Kaye, Andrew H.
Drummond, Katharine J.
Mantamadiotis, Theo
Stylli, Stanley S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11010-022-04584-0
- URN
-
urn:nbn:de:101:1-2023011221032088072279
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jones, Dylan
- Whitehead, Clarissa A.
- Dinevska, Marija
- Widodo, Samuel S.
- Furst, Liam M.
- Morokoff, Andrew P.
- Kaye, Andrew H.
- Drummond, Katharine J.
- Mantamadiotis, Theo
- Stylli, Stanley S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Repurposing of approved cardiovascular drugs
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Repurposing of approved cardiovascular drugs
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation
The First FDA-Approved Antibody-Drug Conjugate
Repurposing FDA-approved drugs for anti-aging therapies
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Repurposing of approved cardiovascular drugs
Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation